ArticleMolecular therapy. Oncology2025
Epigenetic co-regulator HCF-1 promotes lung cancer via O-GlcNAcylation-dependent pathways.
Article in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dysregulation of post-translational modifications in glioma: advances in pathological mechanisms and clinical targeting strategies.Journal of translational medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rise in the incidences of lung cancer currently poses a global health challenge, making it crucial to understand the underlying molecular and cellular mechanisms. Host cell factor-1 (HCF-1), a conserved epigenetic transcriptional co-regulator, undergoes proteolytic maturation and glycosylation by O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT). Elevated O-GlcNAc and OGT levels have been observed in lung cancer, highlighting their potential significance in disease progression. In human lung cancer tissues, we observed a significant upregulation of HCF-1, which coincides with increased OGT, O-GlcNAc, and Nkx2.1 (a diagnostic marker for non-small cell lung cancer [NSCLSC]) levels. To further explore HCF-1's role mechanistically, we utilized the NSCLC cell lines, where HCF-1 depletion resulted in reduced proliferation, O-GlcNAcylation, Nkx2.1 expression, and O-GlcNAcylated proteins upon wheat germ agglutinin (WGA) pull-down, reinforcing its role in lung cancer progression. Additionally, Nkx2.1-mediated conditional knockout of HCF-1 impaired murine lung development and cell proliferation. Interestingly, OGT inhibition with OSMI-1 also reduced HCF-1, Nkx2.1 levels, and proliferation, suggesting a role for O-GlcNAcylation in HCF-1-mediated signaling cascades. Thus, our findings elucidate the critical role of HCF-1 and O-GlcNAcylation in lung cancer pathogenesis. These insights not only deepen our understanding of lung cancer pathogenesis but also identify potential molecular targets for studies aimed at intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.